Publication:
Comparative analysis and characterization of soluble factors and exosomes from cultured adipose tissue and bone marrow mesenchymal stem cells in canine species.

dc.contributor.authorVillatoro, A J
dc.contributor.authorAlcoholado, C
dc.contributor.authorMartín-Astorga, M C
dc.contributor.authorFernández, V
dc.contributor.authorCifuentes, M
dc.contributor.authorBecerra, J
dc.date.accessioned2023-01-25T10:29:48Z
dc.date.available2023-01-25T10:29:48Z
dc.date.issued2018-12-18
dc.description.abstractThe two main sources of mesenchymal stem cell (MSCs) in the canine species are bone marrow (cBM-MSCs) and adipose tissue (cAd-MSCs). The secretion of multitude bioactive molecules, included under the concept of secretome and found in the cultured medium, play a predominant role in the mechanism of action of these cells on tissue regeneration. Although certain features of its characterization are well documented, their secretory profiles remain unknown. We described and compared, for the first time, the secretory profile and exosomes characterization in standard monolayer culture of MSCs from both sources of the same donor as well as its immunomodulatory potential. We found that despite the similarity in surface immunophenotyping and trilineage differentiation, there are several differences in terms of proliferation rate and secretory profile. cAd-MSCs have advantages in proliferative capacity, whereas cBM-MSCs showed a significantly higher secretory production of some soluble factors (IL-10, IL-2, IL-6, IL-8, IL-12p40, IFN-γ, VEGF-A, NGF-β, TGF-β, NO and PGE2) and exosomes under the same standard culture conditions. Proteomics analysis confirm that cBM-MSCs exosomes have a greater number of characterized proteins involved in metabolic processes and in the regulation of biological processes compared to cAd-MSCs. On the other hand, secretome from both sources demonstrate similar immunomodulatory capacity when tested in mitogen stimulated lymphocyte reaction, but not in their exosomes at the dose used. Considering that the use of secretome open as a new therapeutic strategy for different diseases, without the need to implant cells, those biological differences should be considered, when choosing the MSCs source, for either cellular implantation or direct use of secretome for a specific clinical application.
dc.identifier.doi10.1016/j.vetimm.2018.12.003
dc.identifier.essn1873-2534
dc.identifier.pmid30712794
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.vetimm.2018.12.003
dc.identifier.urihttp://hdl.handle.net/10668/13503
dc.journal.titleVeterinary immunology and immunopathology
dc.journal.titleabbreviationVet Immunol Immunopathol
dc.language.isoen
dc.organizationCentro Andaluz de Nanomedicina y Biotecnología-BIONAND
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.page.number6-15
dc.pubmedtypeComparative Study
dc.pubmedtypeJournal Article
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCell therapy
dc.subjectExosomes
dc.subjectMesenchymal stem cells
dc.subjectRegenerative medicine
dc.subjectSecretome
dc.subject.meshAdipose Tissue
dc.subject.meshAnimals
dc.subject.meshBone Marrow Cells
dc.subject.meshCell Differentiation
dc.subject.meshCell Proliferation
dc.subject.meshCells, Cultured
dc.subject.meshCytokines
dc.subject.meshDogs
dc.subject.meshExosomes
dc.subject.meshFemale
dc.subject.meshImmunophenotyping
dc.subject.meshMale
dc.subject.meshMesenchymal Stem Cells
dc.subject.meshProteome
dc.subject.meshProteomics
dc.titleComparative analysis and characterization of soluble factors and exosomes from cultured adipose tissue and bone marrow mesenchymal stem cells in canine species.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number208
dspace.entity.typePublication

Files